See more : El Nino Ventures Inc. (ELNOF) Income Statement Analysis – Financial Results
Complete financial analysis of Thermo Fisher Scientific Inc. (TMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thermo Fisher Scientific Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Alpine 4 Holdings, Inc. (ALPP) Income Statement Analysis – Financial Results
- Genworth Financial, Inc. (GNW) Income Statement Analysis – Financial Results
- Artemis Resources Limited (ARTTF) Income Statement Analysis – Financial Results
- HERBAL DISPATCH INC. (LUFFF) Income Statement Analysis – Financial Results
- Kyokuto Securities Co., Ltd. (8706.T) Income Statement Analysis – Financial Results
Thermo Fisher Scientific Inc. (TMO)
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.86B | 44.92B | 39.21B | 32.22B | 25.54B | 24.36B | 20.92B | 18.27B | 16.97B | 16.89B | 13.09B | 12.51B | 11.73B | 10.79B | 10.11B | 10.50B | 9.75B | 3.79B | 2.63B | 2.21B | 2.10B | 2.09B | 2.19B | 2.28B | 2.47B | 3.87B | 3.56B | 2.93B | 2.21B | 1.59B | 1.25B | 949.00M | 805.50M | 708.00M | 579.00M | 500.60M | 383.40M | 331.60M | 265.70M |
| Cost of Revenue | 25.74B | 25.42B | 18.98B | 15.71B | 13.72B | 12.99B | 10.96B | 9.46B | 8.78B | 8.97B | 7.34B | 6.99B | 6.74B | 6.22B | 5.96B | 6.29B | 5.94B | 2.22B | 1.44B | 1.19B | 1.15B | 1.16B | 1.23B | 1.26B | 1.26B | 2.02B | 1.84B | 1.54B | 1.12B | 866.30M | 713.10M | 579.80M | 510.20M | 443.00M | 384.10M | 325.70M | 248.70M | 219.30M | 174.30M |
| Gross Profit | 17.11B | 19.50B | 20.23B | 16.51B | 11.83B | 11.36B | 9.96B | 8.82B | 8.18B | 7.92B | 5.75B | 5.52B | 4.99B | 4.57B | 4.15B | 4.21B | 3.80B | 1.57B | 1.19B | 1.01B | 948.02M | 927.38M | 958.62M | 1.02B | 1.21B | 1.84B | 1.72B | 1.39B | 1.08B | 719.00M | 536.60M | 369.20M | 295.30M | 265.00M | 194.90M | 174.90M | 134.70M | 112.30M | 91.40M |
| Gross Profit Ratio | 39.93% | 43.42% | 51.60% | 51.23% | 46.30% | 46.65% | 47.60% | 48.24% | 48.23% | 46.89% | 43.93% | 44.10% | 42.54% | 42.39% | 41.04% | 40.07% | 39.03% | 41.36% | 45.38% | 45.99% | 45.21% | 44.45% | 43.81% | 44.81% | 48.81% | 47.65% | 48.36% | 47.40% | 49.05% | 45.35% | 42.94% | 38.90% | 36.66% | 37.43% | 33.66% | 34.94% | 35.13% | 33.87% | 34.40% |
| Research & Development | 1.34B | 1.47B | 1.41B | 1.18B | 1.00B | 967.00M | 888.00M | 754.80M | 692.30M | 691.10M | 395.50M | 376.40M | 340.60M | 287.20M | 246.10M | 249.10M | 238.70M | 170.18M | 152.78M | 134.68M | 146.39M | 155.12M | 171.61M | 176.76M | 171.10M | 367.30M | 337.30M | 0.00 | 269.60M | 103.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.45B | 7.13B | 6.84B | 5.76B | 4.93B | 4.82B | 4.41B | 4.04B | 3.72B | 3.99B | 2.91B | 2.83B | 2.65B | 2.39B | 2.20B | 2.69B | 2.55B | 1.11B | 761.79M | 626.46M | 568.14M | 564.66M | 620.10M | 646.92M | 673.00M | 937.60M | 840.70M | 990.70M | 480.80M | 373.20M | 370.60M | 271.70M | 233.60M | 210.60M | 164.40M | 144.60M | 117.10M | 91.60M | 78.70M |
| Other Expenses | 536.00M | 2.40B | 1.76B | 1.67B | 1.71B | 9.00M | -28.00M | -4.10M | -15.50M | 16.40M | -56.00M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| Operating Expenses | 10.24B | 10.99B | 10.01B | 8.61B | 7.65B | 7.53B | 6.89B | 6.18B | 5.73B | 6.01B | 4.06B | 3.95B | 3.64B | 3.25B | 3.04B | 2.94B | 2.79B | 1.28B | 914.56M | 761.14M | 714.53M | 719.78M | 791.72M | 823.68M | 957.70M | 1.47B | 1.31B | 1.11B | 835.40M | 539.20M | 413.00M | 300.90M | 257.00M | 229.40M | 177.10M | 155.70M | 127.20M | 100.00M | 86.50M |
| Cost & Expenses | 36.00B | 36.41B | 28.99B | 24.33B | 21.36B | 20.53B | 17.85B | 15.64B | 14.51B | 14.98B | 11.40B | 10.95B | 10.38B | 9.46B | 9.00B | 9.23B | 8.73B | 3.50B | 2.35B | 1.95B | 1.86B | 1.88B | 2.02B | 2.08B | 2.22B | 3.49B | 3.15B | 2.65B | 1.96B | 1.41B | 1.13B | 880.70M | 767.20M | 672.40M | 561.20M | 481.40M | 375.90M | 319.30M | 260.80M |
| Interest Income | 879.00M | 272.00M | 43.00M | 65.00M | 224.00M | 137.00M | 81.00M | 48.40M | 30.60M | 47.70M | 28.00M | 25.20M | 26.90M | 12.50M | 16.10M | 51.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.38B | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M | 592.00M | 469.60M | 414.90M | 479.90M | 262.10M | 241.60M | 175.30M | 84.70M | 118.10M | 151.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.41B | 3.38B | 2.59B | 2.33B | 2.28B | 2.27B | 2.03B | 1.76B | 1.69B | 1.68B | 999.90M | 983.70M | 863.50M | 770.00M | 787.30M | 792.70M | 756.80M | 240.77M | 123.27M | 66.14M | 58.55M | 56.38M | 98.52M | 97.49M | 113.60M | 162.30M | 135.70M | 115.20M | 85.00M | 62.30M | 42.40M | 29.20M | 23.40M | 18.80M | 12.70M | 11.10M | 10.10M | 8.40M | 7.80M |
| EBITDA | 11.20B | 11.94B | 12.96B | 10.19B | 6.46B | 6.20B | 5.25B | 4.25B | 4.04B | 4.25B | 2.58B | 2.49B | 2.18B | 1.91B | 1.83B | 2.07B | 1.78B | 502.07M | 435.89M | 336.34M | 279.30M | 193.08M | 265.43M | 295.65M | 362.20M | 353.40M | 371.60M | 399.40M | 332.30M | 242.10M | 166.00M | 97.50M | 61.70M | 54.40M | 30.50M | 30.30M | 17.60M | 20.70M | 12.70M |
| EBITDA Ratio | 26.12% | 26.84% | 31.03% | 31.67% | 25.88% | 25.64% | 24.62% | 24.30% | 24.49% | 21.63% | 20.31% | 20.60% | 19.07% | 19.54% | 18.92% | 19.95% | 18.65% | 15.11% | 14.55% | 14.22% | 14.63% | 9.25% | 16.53% | 13.55% | 23.20% | 13.51% | 12.97% | 10.53% | 9.21% | 10.02% | 12.68% | 4.16% | 0.30% | 2.53% | -0.14% | 1.96% | -1.85% | 3.44% | 0.45% |
| Operating Income | 6.86B | 8.39B | 10.03B | 7.79B | 4.59B | 3.78B | 2.97B | 2.45B | 2.34B | 2.50B | 1.61B | 1.48B | 1.25B | 1.26B | 1.05B | 1.23B | 974.40M | 241.96M | 263.49M | 237.51M | 184.77M | 155.45M | 34.20M | 198.16M | 248.60M | 375.80M | 407.00M | 284.20M | 247.30M | 179.80M | 123.60M | 68.30M | 38.30M | 35.60M | 17.80M | 19.20M | 7.50M | 12.30M | 4.90M |
| Operating Income Ratio | 16.00% | 18.69% | 25.57% | 24.19% | 17.99% | 15.53% | 14.19% | 13.40% | 13.77% | 14.82% | 12.30% | 11.85% | 10.62% | 11.72% | 10.38% | 11.71% | 10.00% | 6.38% | 10.01% | 10.77% | 8.81% | 7.45% | 1.56% | 8.69% | 10.06% | 9.72% | 11.44% | 9.69% | 11.20% | 11.34% | 9.89% | 7.20% | 4.75% | 5.03% | 3.07% | 3.84% | 1.96% | 3.71% | 1.84% |
| Total Other Income/Expenses | -561.00M | -558.00M | -1.19B | -567.00M | -524.00M | -521.00M | -531.00M | -434.10M | -399.60M | -415.80M | -290.10M | -212.70M | -112.40M | -100.30M | -121.80M | -79.80M | -93.10M | -32.59M | -7.88M | 4.78M | 35.25M | 131.50M | 42.32M | -23.90M | -230.10M | -28.30M | -100.30M | 17.40M | -8.30M | -7.20M | -13.60M | 19.80M | 33.70M | 15.40M | 16.40M | 8.20M | 15.20M | 4.90M | 6.90M |
| Income Before Tax | 6.30B | 7.84B | 8.84B | 7.23B | 4.07B | 3.26B | 2.43B | 2.02B | 1.94B | 2.09B | 1.32B | 1.27B | 1.13B | 1.16B | 927.10M | 1.15B | 881.30M | 209.37M | 285.90M | 259.22M | 218.63M | 287.99M | 76.52M | 174.26M | 18.50M | 347.50M | 414.00M | 301.60M | 239.00M | 172.60M | 110.00M | 88.10M | 72.00M | 51.00M | 34.20M | 27.40M | 22.70M | 17.20M | 11.80M |
| Income Before Tax Ratio | 14.70% | 17.44% | 22.55% | 22.43% | 15.93% | 13.39% | 11.61% | 11.08% | 11.41% | 12.36% | 10.08% | 10.15% | 9.61% | 10.79% | 9.17% | 10.95% | 9.04% | 5.52% | 10.86% | 11.75% | 10.43% | 13.80% | 3.50% | 7.64% | 0.75% | 8.98% | 11.63% | 10.28% | 10.83% | 10.89% | 8.80% | 9.28% | 8.94% | 7.20% | 5.91% | 5.47% | 5.92% | 5.19% | 4.44% |
| Income Tax Expense | 284.00M | 703.00M | 1.11B | 850.00M | 374.00M | 324.00M | 201.00M | -1.40M | -43.90M | 191.70M | 40.40M | 11.00M | 107.00M | 131.50M | 75.80M | 160.90M | 101.70M | 43.05M | 87.60M | 40.85M | 45.94M | 92.99M | 26.93M | 112.22M | 33.10M | 170.70M | 174.70M | 110.80M | 98.90M | 69.20M | 33.40M | 27.50M | 24.90M | 17.10M | 9.60M | 7.30M | 4.60M | 2.90M | 2.20M |
| Net Income | 6.00B | 6.95B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B | 1.98B | 1.89B | 1.27B | 1.18B | 1.33B | 1.04B | 850.30M | 994.20M | 761.10M | 168.94M | 223.22M | 361.84M | 200.01M | 309.73M | -781.00K | -36.11M | -174.60M | 181.90M | 239.30M | 190.80M | 140.10M | 103.40M | 76.60M | 59.20M | 47.10M | 33.90M | 24.60M | 20.10M | 18.10M | 14.30M | 9.60M |
| Net Income Ratio | 13.99% | 15.47% | 19.70% | 19.79% | 14.47% | 12.06% | 10.64% | 11.06% | 11.64% | 11.22% | 9.73% | 9.42% | 11.34% | 9.60% | 8.41% | 9.47% | 7.81% | 4.46% | 8.48% | 16.40% | 9.54% | 14.85% | -0.04% | -1.58% | -7.07% | 4.70% | 6.73% | 6.51% | 6.35% | 6.52% | 6.13% | 6.24% | 5.85% | 4.79% | 4.25% | 4.02% | 4.72% | 4.31% | 3.61% |
| EPS | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | 5.64 | 5.12 | 4.96 | 4.76 | 3.53 | 3.24 | 3.49 | 2.57 | 2.06 | 2.34 | 1.81 | 0.86 | 1.38 | 2.22 | 1.23 | 1.84 | 0.00 | -0.22 | -1.11 | 1.12 | 1.57 | 1.35 | 1.11 | 0.93 | 0.33 | 0.18 | 0.17 | 0.14 | 0.11 | 0.10 | 0.09 | 0.07 | 0.04 |
| EPS Diluted | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | 5.59 | 5.09 | 4.92 | 4.71 | 3.48 | 3.21 | 3.46 | 2.53 | 2.01 | 2.25 | 1.72 | 0.84 | 1.36 | 2.17 | 1.20 | 1.73 | 0.00 | -0.22 | -1.10 | 1.08 | 1.41 | 1.22 | 0.99 | 0.82 | 0.29 | 0.17 | 0.16 | 0.13 | 0.10 | 0.09 | 0.09 | 0.07 | 0.04 |
| Weighted Avg Shares Out | 386.00M | 392.00M | 394.00M | 396.00M | 400.00M | 402.00M | 395.00M | 394.80M | 398.70M | 398.20M | 360.30M | 363.80M | 380.80M | 403.30M | 412.40M | 418.20M | 421.50M | 196.10M | 161.59M | 163.13M | 162.71M | 168.33M | 181.59M | 164.14M | 157.99M | 162.41M | 152.48M | 141.53M | 125.48M | 110.80M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
| Weighted Avg Shares Out (Dil) | 388.00M | 394.00M | 397.00M | 399.00M | 403.00M | 406.00M | 398.00M | 397.40M | 401.90M | 402.30M | 365.80M | 366.60M | 384.80M | 409.40M | 423.03M | 434.70M | 443.70M | 203.70M | 165.33M | 167.64M | 170.73M | 179.03M | 185.02M | 164.14M | 158.22M | 168.43M | 169.79M | 175.70M | 158.10M | 145.53M | 107.71M | 91.04M | 87.06M | 70.60M | 61.06M | 58.72M | 57.91M | 58.74M | 48.80M |
TMO Stock to Gain From the New Additions to CTS Portfolio of Products
Thermo Fisher launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to enhance cell therapy development and production.
Thermo Fisher: M&A And Innovation To Drive Sales Growth
The reduction in revenues due to the decline in COVID-19-related products and services is expected to diminish or disappear in 2025. Thermo Fisher has been growing by acquiring other companies. This strategy led to the company growing 174% between 2017...
Thermo Fisher Scientific Launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to Enhance Cell Therapy Development and Production
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8 (CTS Detachable Dynabeads)*. These latest products expand on Thermo Fisher's CTS Detachable Dynabeads platform, which...
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3.
End Market Growth, New Acquisitions Drive Thermo Fisher's Shares
A few of its recent strategic acquisitions that are likely to drive future growth for TMO include the $3.1-billion acquisition of Olink Holdings.
Thermo Fisher Scientific Inc. (TMO) Wolfe 2024 Healthcare Conference (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) Wolfe 2024 Healthcare Results Conference November 19, 2024 8:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right....
Thermo Fisher Scientific Authorizes $4 Billion of Share Repurchases
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in...
Thermo Fisher Scientific: Near The Bottom And Attractively Valued
Thermo Fisher Scientific has strong growth prospects due to easing COVID-19 headwinds, improving Chinese and biotech markets, and favorable funding environments. The company's margins should benefit from volume leverage, cost-saving initiatives, M&A synergies, and favorable price/mix as organic growth improves....
Thermo Fisher Scientific to Present at the Wolfe 2024 Healthcare Conference on November 19, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Wolfe Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m....
Thermo Fisher Scientific Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on January 15, 2025, to shareholders of record...
Source: https://incomestatements.info
Category: Stock Reports